Advertisement

Part V: A Critical Summary

  • J. C. Heuson
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 91)

Abstract

The three papers presented in this section involve some consideration of the potential usefulness of estrogen receptors (ER) in the planning of adjuvant therapy for breast cancer. Hence the problem is briefly reviewed.

Keywords

Breast Cancer Estrogen Receptor Primary Breast Cancer Adjuvant Trial Hormone Dependence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Háhnel R (1982) Steroid receptor status, tumor growth and prognosis. In: Stoll BA (ed) Endocrine relationship in breast cancer. Heinemann Medical, London, p 107Google Scholar
  2. 2.
    Knight WA III, Livingston RB, Gregory EJ, McGuire WL (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37: 4669PubMedGoogle Scholar
  3. 3.
    Bonadonna G, Bignami P, Buzzoni R, Moliterni A, Valagussa P, Veronesi U (1983) New adjuvant trials for resectable breast cancer at the Istituto Nazionale Tumori of Milan. This book, pp 210–213Google Scholar
  4. 4.
    DeSombre ER, Carbone PP, Jensen EV, McGuire WL, Wells SA Jr, Wittliff JL, Lipsett MB (1979) Steroid receptors in breast cancer. N Engl J Med 301: 1011PubMedCrossRefGoogle Scholar
  5. 5.
    Heuson JC, Longeval E, Mattheiem WH, Deboel C, Sylvester RJ, Leclerq G (1977) Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer. Cancer 39: 1971PubMedCrossRefGoogle Scholar
  6. 6.
    Paridaens R, Sylvester RJ, Ferrazzi E, Legros N, Leclercq G, Heuson JC (1980) Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 46: 2889PubMedCrossRefGoogle Scholar
  7. 7.
    Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884PubMedCrossRefGoogle Scholar
  8. 8.
    Palshof T (1981) Adjuvant endocrine therapy in the management of primary breast cancer. Reviews on Endocrine-Related Cancer (Suppl) 7: 65Google Scholar
  9. 9.
    Wallgren A, Baral E, Glas U, Kaigas M, Karnstróm L, Nordenskjóld B, Theve NO, Wilking N, Silfverswárd C (1981) Adjuvant breast cancer treatment with tamoxifen and combination chemotherapy in post-menopausal women. In: Salmon S, Jones SE (eds) Adjuvant therapy of cancer III. Grune and Stratton, New York, p 345Google Scholar
  10. 10.
    Hubay CA, Pearson OH, Marshall JS, Rhodes RS et al. (1980) Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial. Cancer 46: 2805PubMedCrossRefGoogle Scholar
  11. 11.
    Fisher B, Redmond C, Brown A, Wolmark N et al. (1981) Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305: 1PubMedCrossRefGoogle Scholar
  12. 12.
    Sarfaty GA, Nash AR, Keightley DD (eds) (1981) Estrogen receptor assay in breast cancer. Laboratory discrepancies and quality assurance. Masson, New YorkGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1984

Authors and Affiliations

  • J. C. Heuson
    • 1
  1. 1.Institut Jules Bordet, Centre des Tumeurs, Service de Médecine, Clinique et Laboratoire de Cancérologie Mammairel’Université Libre de BruxellesBruxellesBelgium

Personalised recommendations